AINostics
Generated by Meeveem AI
"AI powered diagnostics for early detection of neurological disorders using medical imaging"
Manchester
•11 - 50 Employees
•Digital Health
About AINostics
AINOSTICS commercialises over two decades of research into diagnosing neurological disorders through artificial intelligence. The company provides an automated platform that assists clinical diagnosis using multi-modal imaging and non-imaging data. Its flagship product, BR[AI]N®, holds FDA Breakthrough Device status for predicting conversion to Alzheimer's disease using structural MRI scans. The company identifies the earliest biological signs of Alzheimer's, Multiple Sclerosis, stroke and brain tumours. By combining medical imaging with AI algorithms, AINOSTICS improves workflow across the clinical imaging pathway, empowering clinicians to deliver faster, more accurate care whilst supporting pharmaceutical companies in drug development.
13
Team Members
2018
Founded
Digital Health
Sector
Hybrid
Work Environment
Our Vision
Neurological diseases detected years before symptoms emerge, enabling preventions and treatments to succeed when intervention matters most, transforming patient outcomes through the fusion of imaging science and artificial intelligence.
Our Mission
AINOSTICS exists to commercialise groundbreaking research that addresses unmet clinical needs by providing automated, extensible AI solutions for diagnosing and monitoring tissue modifying diseases through multi-modal medical data analysis.